Induced pluripotent stem cells: at the heart of cardiovascular precision medicine
Open accessAbstract
The advent of human induced pluripotent stem cell (hiPSC) technology has revitalized the efforts in the past decade to realize more fully the potential of human embryonic stem cells for scientific research. Adding to the possibility of generating an unlimited amount of any cell type of interest, hiPSC technology now enables the derivation of cells with patient-specific phenotypes. Given the introduction and implementation of the large-scale Precision Medicine Initiative, hiPSC technology will undoubtedly have a vital role in the advancement of cardiovascular research and medicine. In this Review, we summarize the progress that has been made in the field of hiPSC technology, with particular emphasis on cardiovascular disease modelling and drug development. The growing roles of hiPSC technology in the practice of precision medicine will also be discussed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
hiPSC-CMs offer clinical opportunities to study heritable cardiovascular diseases, test drug candidates, and enable cardiac regeneration and precision medicine.
“While patient tissue samples are the most relevant for disease studies, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer unprecedented clinical opportunities to study heritable cardiovascular diseases, test various drug candidates, and enable cardiac regeneration and precision medicine [150].”
From Top-down proteomics: challenges, innovations, and applications in basic and clinical research (2020) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 185 · Cited by 191
- Authors
- Chen, I. Y., Matsa, E., & Wu, J. C.
- Affiliations
- Stanford Medicine (US)
- Stanford Cardiovascular Institute (US)
- Corresponding author
- Wu, Joseph C.
- Venue
- Nature Reviews Cardiology
- Published
- 2016-03-24
- Volume
- 13
- Issue
- 6
- Pages
- 333-349
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- PMC
- PMC5917945
- OpenAlex
- W2323091991
- Cited by
- 191
- References
- 185
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 18 · 2023: 9 · 2022: 18 · 2021: 25 · 2020: 20 · 2019: 19 · 2018: 23 · 2017: 22 · 2016: 15
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Health and Environmental Sciences Institute
- National Institutes of Health
- School of Medicine, Stanford University
- National Heart, Lung, and Blood Institute (R01HL123968, R01HL128170, R01HL126527, R01HL130020)
- National Institute of Biomedical Imaging and Bioengineering (T32EB009035)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
- Keywords
- induced pluripotent stem cells, cardiovascular drug development, cardiomyocytes, endothelial cells, patient-specific cell models, precision medicine, personalized treatment, iPSC-derived cells
- MeSH terms
- Cellular Reprogramming Techniques, Cardiovascular Diseases, Cell Differentiation, Humans, Models, Cardiovascular, Myocytes, Cardiac, Myocytes, Smooth Muscle, Endothelial Cells, Drug Discovery, Induced Pluripotent Stem Cells, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
